Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.43 |
| ▸ | DAO | P14920 | 4/20 | 0.42 |
| ▸ | HNF4A | P41235 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22071237 | 0.88 | DAO (0.52) | RAB9AMEN1POLBKMT2ADAO | |
| SCHEMBL7082765 | 0.86 | L3MBTL1 (0.57) | RAB9AAPPFFAR1KDM4EL3MBTL1 | |
| SCHEMBL17057395 | 0.77 | DAO (0.43) | RAB9AMEN1POLBKMT2ADAO | |
| SCHEMBL3586108 | 0.77 | KDM4E (0.53) | RAB9AMEN1POLBKMT2AFFAR1 | |
| SCHEMBL11303711 | 0.77 | ALDH1A1 (0.50) | RAB9AHPGDKDM4ENPC1ALDH1A1 | |
| SCHEMBL23440050 | 0.76 | APP (0.39) | RAB9AMEN1KMT2AAPPFFAR1 | |
| SCHEMBL10688017 | 0.76 | KDM4E (0.48) | RAB9AMEN1POLBKMT2AHPGD | |
| SCHEMBL16056864 | 0.74 | DAO (0.42) | RAB9AMEN1POLBKMT2ADAO | |
| SCHEMBL3685351 | 0.74 | MGLL (0.36) | RAB9AFFAR1NPC1 | |
| SCHEMBL5162659 | 0.74 | DAO (0.50) | RAB9AMEN1POLBKMT2ADAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296972-B1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7317031-B2 | Substituted triazole diamine derivatives as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| EP-1712550-A2 | Substituted triazole diamine derivatives as kinase inhibitors | Ortho-McNeil Pharmaceutical, Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| US-6977263-B2 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050228018-A1 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20050182116-A1 | Substituted triazole diamine derivatives as kinase inhibitors | LIN RONGHUI (US) | 2005-08-18 | — | — | US | disclosed |
| US-6924302-B2 | Substituted triazole diamine derivatives as kinase inhibitors | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2005-08-02 | — | — | US | disclosed |
| US-20030187020-A1 | Chemical compounds | AVENTISUB LLC | 2003-10-02 | — | — | US | disclosed |
| EP-1296972-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182116-A1 | Substituted triazole diamine derivatives as kinase inhibitors | MAP2K2, PRKDC, MAP2K3 | RAB9A 2239/4885MEN1 2738/4885POLB 1798/4885 |
| US-20050228018-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | RAB9A 1607/4885MEN1 2733/4885POLB 3914/4885 |
| US-20030187020-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | RAB9A 1607/4885MEN1 2733/4885POLB 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.